JP2009528340A - 癌治療 - Google Patents

癌治療 Download PDF

Info

Publication number
JP2009528340A
JP2009528340A JP2008556861A JP2008556861A JP2009528340A JP 2009528340 A JP2009528340 A JP 2009528340A JP 2008556861 A JP2008556861 A JP 2008556861A JP 2008556861 A JP2008556861 A JP 2008556861A JP 2009528340 A JP2009528340 A JP 2009528340A
Authority
JP
Japan
Prior art keywords
oxaliplatin
liposome
cancer
liposomes
encapsulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008556861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528340A5 (enExample
Inventor
ブリカス，パルテニオス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2009528340A publication Critical patent/JP2009528340A/ja
Publication of JP2009528340A5 publication Critical patent/JP2009528340A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008556861A 2006-03-03 2007-03-05 癌治療 Pending JP2009528340A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR20060100144A GR20060100144A (el) 2006-03-03 2006-03-03 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
PCT/GR2007/000015 WO2007099377A2 (en) 2006-03-03 2007-03-05 Cancer treatments

Publications (2)

Publication Number Publication Date
JP2009528340A true JP2009528340A (ja) 2009-08-06
JP2009528340A5 JP2009528340A5 (enExample) 2010-04-22

Family

ID=38325437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008556861A Pending JP2009528340A (ja) 2006-03-03 2007-03-05 癌治療

Country Status (17)

Country Link
US (1) US20090053302A1 (enExample)
EP (1) EP2001441A2 (enExample)
JP (1) JP2009528340A (enExample)
KR (1) KR20090023548A (enExample)
CN (1) CN101522172A (enExample)
AU (1) AU2007220263A1 (enExample)
BR (1) BRPI0707059A2 (enExample)
CA (1) CA2644566A1 (enExample)
EA (1) EA200801912A1 (enExample)
GR (1) GR20060100144A (enExample)
MA (1) MA30314B1 (enExample)
MX (1) MX2008011263A (enExample)
NO (1) NO20083927L (enExample)
RS (1) RS20080388A (enExample)
TN (1) TNSN08345A1 (enExample)
WO (1) WO2007099377A2 (enExample)
ZA (1) ZA200807934B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011211996A (ja) * 2010-04-02 2011-10-27 Chiba Univ 腫瘍特異性を有するリポソーム
JP2013505291A (ja) * 2009-09-21 2013-02-14 ジェイダブリュー ファーマシューティカル コーポレイション オキサリプラチンのナノ粒子及びその製造方法
WO2013022052A1 (ja) * 2011-08-11 2013-02-14 学校法人日本歯科大学 医療用薬剤および新規薬剤探索方法
WO2014025042A1 (ja) * 2012-08-10 2014-02-13 大鵬薬品工業株式会社 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
WO2014157444A1 (ja) * 2013-03-27 2014-10-02 大鵬薬品工業株式会社 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
JP2015524467A (ja) * 2012-08-13 2015-08-24 レギュロン、インク.Regulon, Inc. Ｌｉｐｏｐｌａｔｉｎを使用するがんの処置方法
JP2018505224A (ja) * 2015-02-13 2018-02-22 オーピーナノ シーオー エルティーディーＯＰ Ｎａｎｏ Ｃｏ．，Ｌｔｄ． ナノ粒子を含む組成物並びに腫瘍を治療する方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
KR20080094473A (ko) * 2007-04-20 2008-10-23 한국화학연구원 음이온성 지질나노입자 및 이의 제조방법
ES2465477T3 (es) * 2008-01-28 2014-06-05 Nanocarrier Co., Ltd. Composición farmacéutica y fármaco combinado
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
EP2259844A4 (en) * 2008-03-05 2012-02-01 Vicus Therapeutics Llc COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGICAL THERAPIES
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
WO2010138550A1 (en) * 2009-05-27 2010-12-02 Northeastern University Conjugated nanodelivery vehicles
CN102133176B (zh) * 2011-03-22 2012-09-05 济南宏瑞创博医药科技开发有限公司 一种奥沙利铂胶束制剂及其制备方法及应用
MA37931A1 (fr) * 2012-08-13 2016-07-29 Teni Boulikas Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite
EP2892524B1 (en) 2012-09-04 2020-11-25 Eleison Pharmaceuticals, LLC Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
EA023757B1 (ru) * 2012-12-24 2016-07-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы оксалиплатина
EP2968144A1 (en) * 2013-03-13 2016-01-20 Mallinckrodt LLC Liposome oxaliplatin compositions for cancer therapy
CN103622912B (zh) * 2013-12-05 2016-02-24 常州金远药业制造有限公司 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法
WO2016141161A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
KR101687735B1 (ko) * 2015-09-18 2016-12-19 서울대학교 산학협력단 신규의 동결건조보조제 및 새로운 인지질 용해용 혼합용매를 이용한 리포좀 동결분체의 제조방법
WO2017192502A1 (en) * 2016-05-03 2017-11-09 The American University In Cairo Liposomal delivery systems for oxaliplatin and in dual drug delivery in combination with chemo-sensitizing and chemo-therapeutic agents
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN106074379B (zh) * 2016-07-11 2019-01-25 中国科学院上海药物研究所 聚乙二醇化奥沙利铂前药及其制备方法和用途
CN112656764B (zh) * 2020-12-28 2022-09-02 吉林大学 一种紫杉醇铂类共载靶向长循环脂质体及应用
CN114814023B (zh) * 2022-04-24 2024-07-30 江苏省中医院 脂质分子在作为胃癌化疗药耐药的预测性标志物中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194191A (ja) * 1990-07-16 1993-08-03 Dai Ichi Seiyaku Co Ltd リポソーム製剤
JP2003513911A (ja) * 1999-11-05 2003-04-15 ブリカス，テニ シスプラチン及び他の薬剤又はリポソーム中に封入された遺伝子を用いてのヒト癌のための療法
US20030147945A1 (en) * 2001-10-03 2003-08-07 Paul Tardi Compositions for delivery of drug combinations
JP2003535832A (ja) * 2000-06-09 2003-12-02 ブリカス，テニ ポリヌクレオチドおよび薬物の標的化リポソームへのカプセル化
JP2004010481A (ja) * 2002-06-03 2004-01-15 Mebiopharm Co Ltd リポソーム製剤
WO2005000266A2 (en) * 2003-05-22 2005-01-06 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
JP2006502233A (ja) * 2002-08-02 2006-01-19 トランセーブ，インク． 白金凝集物およびその製造方法
JP2006525368A (ja) * 2003-05-02 2006-11-09 アロネックス，ファーマシューティカルズ，インコーポレーテッド 脂質白金錯体およびその使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060080A (en) * 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194191A (ja) * 1990-07-16 1993-08-03 Dai Ichi Seiyaku Co Ltd リポソーム製剤
JP2003513911A (ja) * 1999-11-05 2003-04-15 ブリカス，テニ シスプラチン及び他の薬剤又はリポソーム中に封入された遺伝子を用いてのヒト癌のための療法
JP2003535832A (ja) * 2000-06-09 2003-12-02 ブリカス，テニ ポリヌクレオチドおよび薬物の標的化リポソームへのカプセル化
US20030147945A1 (en) * 2001-10-03 2003-08-07 Paul Tardi Compositions for delivery of drug combinations
JP2004010481A (ja) * 2002-06-03 2004-01-15 Mebiopharm Co Ltd リポソーム製剤
JP2006502233A (ja) * 2002-08-02 2006-01-19 トランセーブ，インク． 白金凝集物およびその製造方法
JP2006525368A (ja) * 2003-05-02 2006-11-09 アロネックス，ファーマシューティカルズ，インコーポレーテッド 脂質白金錯体およびその使用方法
WO2005000266A2 (en) * 2003-05-22 2005-01-06 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN5009004709; ＢＯＵＬＩＫＡＳ，Ｔ．: '"Ｌｉｐｏｓｏｍａｌｌｙ　ｅｎｃａｐｓｕｌａｔｅｄ　ｃｉｓｐｌａｔｉｎ　（Ｌｉｐｏｐｌａｔｉｎ）　ａｎｄ　ｏｘａｌｉｐｌａｔｉｎ　（Ｌｉｐｏｘａｌ）　ａｓ　ｒｅｖｏｌｕｔｉｏｎａｒｙ　ｃｈｅｍｏｔｈｅ' ＰＲＯＣＥＥＤＩＮＧＳ　ＯＦ　ＴＨＥ　８ＴＨ　ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＣＯＮＦＥＲＥＮＣＥ：　"ＥＭＥＲＧＩＮＧ　ＴＥＣＨＮＯＬＯＧＩＥＳ　ＩＮ　ＤＲＵＧ　ＡＮＤ　ＧＥＮＥ-ＢＡＳＥＤ　ＴＨＥＲＡ , 20050903, ＰＰ．５，２１ *
JPN5009004710; ＴＡＫＡＳＡＫＩ，Ｊ．，ＥＴ　ＡＬ．: '"Ｍｉｃｅｌｌｅｓ　ａｓ　Ｉｎｔｅｒｍｅｄｉａｔｅｓ　ｉｎ　ｔｈｅ　Ｐｒｅｐａｒａｔｉｏｎ　ｏｆ　Ｐｒｏｔｅｉｎ-Ｌｉｐｏｓｏｍｅ　Ｃｏｎｊｕｇａｔｅｓ"' ＢＩＯＣＯＮＪＵＧＡＴＥ　ＣＨＥＭＩＳＴＲＹ ＶＯＬ．１７，ＮＯ．２, 20060112, ＰＰ．４３８-４５０ *
JPN5009004711; ＳＴＡＴＨＯＰＯＵＬＯＳ，Ｇ．　Ｐ．，ＥＴ　ＡＬ．: '"Ｌｉｐｏｓｏｍａｌ　Ｏｘａｌｉｐｌａｔｉｎ　ｉｎ　ｔｈｅ　Ｔｒｅａｔｍｅｎｔ　ｏｆ　Ａｄｖａｎｃｅｄ　Ｃａｎｃｅｒ：　Ａ　Ｐｈａｓｅ　Ｉ　Ｓｔｕｄｙ"' ＡＮＴＩＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ ＶＯＬ．２６, 2006, ＰＰ．１４８９-１４９４ *
JPN5009004712; ＦＥＤＩＥＲ，Ａ．，ＥＴ　ＡＬ．: '"ＭＬＨ１-ｄｅｆｉｃｉｅｎｔ　ｔｕｍｏｒ　ｃｅｌｌｓ　ａｒｅ　ｒｅｓｉｓｔａｎｔ　ｔｏ　ｌｉｐｏｐｌａｔｉｎ，　ｂｕｔ　ｒｅｔａｉｎ　ｓｅｎｓｉｔｉｖｉｔｙ　ｔｏ　ｌｉｐｏｘａｌ"' ＡＮＴＩ-ＣＡＮＣＥＲ　ＤＲＵＧＳ ＶＯＬ．１７，ＮＯ．３, 2006, ＰＰ．３１５-３２３ *
JPN5009004713; ＢＯＵＬＩＫＡＳ，Ｔ．，ＥＴ　ＡＬ．: '"Ｌｉｐｏｓｏｍａｌｌｙ　ｅｎｃａｐｓｕｌａｔｅｄ　ｃｉｓｐｌａｔｉｎ　ａｎｄ　ｏｘａｌｉｐｌａｔｉｎ　ａｓ　ｒｅｖｏｌｕｔｉｏｎａｒｙ　ｃｈｅｍｏｔｈｅｒａｐｙ　ｄｒｕｇｓ"' ＡＮＴＩＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ ＶＯＬ．２４, 2004, ＰＰ．４２６５-４２６６ *
JPN5009004714; ＨＥＩＮＥＭＡＮＮ，Ｖ．，ＥＴ　ＡＬ．: '"Ｇｅｍｃｉｔａｂｉｎｅ　ａｎｄ　ｃｉｓｐｌａｔｉｎ　ｉｎ　ｔｈｅ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ａｄｖａｎｃｅｄ　ｏｒ　ｍｅｔａｓｔａｔｉｃ　ｐａｎｃｒｅａｔｉｃ　ｃａｎｃｅｒ"' ＡＮＮＡＬＳ　ＯＦ　ＯＮＣＯＬＯＧＹ ＶＯＬ．１１, 2000, ＰＰ．１３９９-１４０３ *
JPN5009004715; ＢＡＵＫＮＥＣＨＴ，Ｔ．，ＥＴ　ＡＬ．: '"Ｇｅｍｃｉｔａｂｉｎｅ　ｃｏｍｂｉｎｅｄ　ｗｉｔｈ　ｃｉｓｐｌａｔｉｎ　ａｓ　ｆｉｒｓｔ-ｌｉｎｅ　ｔｒｅａｔｍｅｎｔ　ｉｎ　ｐａｔｉｅｎｔｓ　６０　ｙｅａｒｓ　ｏｒ　ｏｌｄｅｒ　ｗｉｔｈ　ｅｐｉｔ' ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＪＯＵＲＮＡＬ　ＯＦ　ＧＹＮＥＣＯＬＯＧＩＣＡＬ　ＣＡＮＣＥＲ ＶＯＬ．１３, 2003, ＰＰ．１３０-１３７ *
JPN5009004716; ＦＯＵＮＴＺＩＬＡＳ，Ｇ．，ＥＴ　ＡＬ．: '"Ｐａｃｌｉｔａｘｅｌ　ａｎｄ　ｇｅｍｃｉｔａｂｉｎｅ　ｖｓ．　ｐａｃｌｉｔａｘｅｌ　ａｎｄ　ｐｅｇｙｌａｔｅｄ　ｌｉｐｏｓｏｍａｌ　ｄｏｘｏｒｕｂｉｃｉｎ　ｉｎ　ａｄｖａｎｃｅｄ　ｎｏｎ-ｎａｓｏｐ' ＥＵＲＯＰＥＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＡＮＣＥＲ．　ＳＵＰＰＬＥＭＥＮＴ , 200510, Ｐ．２８６ *
JPN5009004717; ＭＣＫＥＡＧＥ，Ｍ．　Ｊ．，ＥＴ　ＡＬ．: '"Ｎｅｗ-ｇｅｎｅｒａｔｉｏｎ　ｐｌａｔｉｎｕｍ　ｄｒｕｇｓ　ｉｎ　ｔｈｅ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ｃｉｓｐｌａｔｉｎ-ｒｅｓｉｓｔａｎｔ　ｃａｎｃｅｒｓ"' ＥＸＰＥＲＴ　ＯＰＩＮＩＯＮ　ＯＮ　ＩＮＶＥＳＴＩＧＡＴＩＯＮＡＬ　ＤＲＵＧＳ ＶＯＬ．１４，ＮＯ．８, 2005, ＰＰ．１０３３-１０４６ *
JPN6012048672; ＫＵＬＬＢＥＲＧ，Ｅ．　Ｂ．，ＥＴ　ＡＬ．: '"Ｄｅｖｅｌｏｐｍｅｎｔ　ｏｆ　ＥＧＦ-Ｃｏｎｊｕｇａｔｅｄ　Ｌｉｐｏｓｏｍｅｓ　ｆｏｒ　Ｔａｒｇｅｔｅｄ　Ｄｅｌｉｖｅｒｙ　ｏｆ　Ｂｏｒｏｎａｔｅｄ　ＤＮＡ-Ｂｉｎｄｉｎｇ　Ａｇｅｎｔｓ"' ＢＩＯＣＯＮＪＵＧＡＴＥ　ＣＨＥＭＩＳＴＲＹ ＶＯＬ．１３，ＮＯ．４, 2002, ＰＰ．７３７-７４３ *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505291A (ja) * 2009-09-21 2013-02-14 ジェイダブリュー ファーマシューティカル コーポレイション オキサリプラチンのナノ粒子及びその製造方法
JP2011211996A (ja) * 2010-04-02 2011-10-27 Chiba Univ 腫瘍特異性を有するリポソーム
WO2013022052A1 (ja) * 2011-08-11 2013-02-14 学校法人日本歯科大学 医療用薬剤および新規薬剤探索方法
JP2013040109A (ja) * 2011-08-11 2013-02-28 Nippon Dental Univ 医療用薬剤および新規薬剤探索方法
US9333266B2 (en) 2011-08-11 2016-05-10 The Nippon Dental University Medicinal agent for medical applications
US10383822B2 (en) 2012-08-10 2019-08-20 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
WO2014025042A1 (ja) * 2012-08-10 2014-02-13 大鵬薬品工業株式会社 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
US10993913B2 (en) 2012-08-10 2021-05-04 Taiho Pharmaceutical Co., Ltd Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
JPWO2014025042A1 (ja) * 2012-08-10 2016-07-25 大鵬薬品工業株式会社 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
JP2015524467A (ja) * 2012-08-13 2015-08-24 レギュロン、インク.Regulon, Inc. Ｌｉｐｏｐｌａｔｉｎを使用するがんの処置方法
US9616081B2 (en) 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
RU2668125C2 (ru) * 2013-03-27 2018-09-26 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат
JPWO2014157444A1 (ja) * 2013-03-27 2017-02-16 大鵬薬品工業株式会社 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
WO2014157444A1 (ja) * 2013-03-27 2014-10-02 大鵬薬品工業株式会社 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
JP2018505224A (ja) * 2015-02-13 2018-02-22 オーピーナノ シーオー エルティーディーＯＰ Ｎａｎｏ Ｃｏ．，Ｌｔｄ． ナノ粒子を含む組成物並びに腫瘍を治療する方法

Also Published As

Publication number Publication date
MA30314B1 (fr) 2009-04-01
MX2008011263A (es) 2008-12-12
ZA200807934B (en) 2009-11-25
BRPI0707059A2 (pt) 2011-04-19
AU2007220263A1 (en) 2007-09-07
EA200801912A1 (ru) 2009-02-27
CA2644566A1 (en) 2007-09-07
RS20080388A (sr) 2009-07-15
WO2007099377A2 (en) 2007-09-07
GR20060100144A (el) 2007-10-17
EP2001441A2 (en) 2008-12-17
TNSN08345A1 (en) 2009-12-29
CN101522172A (zh) 2009-09-02
US20090053302A1 (en) 2009-02-26
KR20090023548A (ko) 2009-03-05
WO2007099377A3 (en) 2008-04-17
NO20083927L (no) 2008-09-15

Similar Documents

Publication Publication Date Title
JP2009528340A (ja) 癌治療
Jia et al. A novel dexamethasone-loaded liposome alleviates rheumatoid arthritis in rats
Pillai Nanotechnology toward treating cancer: A comprehensive review
US20250000796A1 (en) Stabilizing Camptothecin Pharmaceutical Compositions
Liu et al. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent
Kim et al. In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer
Riahi et al. Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation
JP2006523713A (ja) 薬剤併用物送達用組成物
Marzban et al. Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies
CN116635009A (zh) 用于递送抗癌剂的具有改进的治疗指数的组合物和方法
CN108883068A (zh) 使用紫杉烷的阳离子微脂体制剂、紫杉烷的非微脂体制剂和其他活性药剂合并治疗乳癌的方法
CN113840624B (zh) 单醣标记的纳米脂质体药物递送系统，其制法及其作为药物靶定递送载体的应用
US10925831B2 (en) Liposomal formulations of platinum-acridine anticancer agents and methods thereof
US20240398725A1 (en) Nanoparticles for cancer treatment
US20220296514A1 (en) Composition and Method of Preparation for Lipid Formulations Comprising Charged Lipids
US20200390702A1 (en) Liposomal taxanes for treatment of sclc
Önol Development of Doxorubicin Loaded Liposomes Self-Assembled With Polysaccharides for Breast Cancer Therapy
HK40070304A (en) Stabilizing camptothecin pharmaceutical compositions
HK40065453A (en) Stabilizing camptothecin pharmaceutical compositions
Feitosa Incorporation of the antitumor drug miltefosine into polymeric micelles
HK40086650A (zh) 用於治疗癌症和癌症耐药性的脂质体制剂
Udofot Development of theranostic pH-sensitive liposomal nanoparticle for early detection and treatment of colon cancer
Rathi Development and Characterization of Functionalized Nanoconstructs for Effective Treatment of Lung Cancer
Alqahtani Evaluating the Cellular Uptake of Cell Membrane Lipid-extracted Nanoliposomes and Corresponding Cytotoxic Drug Activity Using Cellular Models of Human Pancreatic Cancer
HK1258407B (en) Stabilizing camptothecin pharmaceutical compositions

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130521